Hepatic PGC-1β overexpression induces combined hyperlipidemia and modulates the response to PPARα activation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 12, 2007, Pages 2707-2713

  Lelliott, Christopher J ^a   Ljungberg, Anna ^a,b,c   Ahnmark, Andrea ^a   William Olsson, Lena ^a   Ekroos, Kim ^a,b,d   Elmgren, Anders ^a   Arnerup, Gunnel ^e   Shoulders, Carol C ^f   Oscarsson, Jan ^a,b,c   Lindén, Daniel ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^e ASTRAZENECA R AND D   (Sweden)

^f MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

Adenovirus; Apolipoprotein B; DGAT; Hepatic lipase; Hypertriglyceridemia

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; FAS ANTIGEN; LIVER TRIACYLGLYCEROL LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; ACETYL COENZYME A CARBOXYLASE; CD36 ANTIGEN; CD36 PROTEIN, RAT; DGAT1 PROTEIN, MOUSE; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; FATTY ACID SYNTHASE; HYPOCHOLESTEROLEMIC AGENT; LIPC PROTEIN, MOUSE; LIPOPROTEIN RECEPTOR; MESSENGER RNA; PIRINIXIC ACID; PPARGC1A PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSACTIVATOR PROTEIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE SECRETION; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE EXPRESSION; HYPERLIPIDEMIA; LIPID DIET; LIVER DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; FAMILIAL HYPERLIPEMIA; FAT INTAKE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LIPID METABOLISM; LIVER; METABOLISM; UPREGULATION;

ACETYL-COA CARBOXYLASE; ADENOVIRIDAE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD36; APOLIPOPROTEINS B; CELLS, CULTURED; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; GENE EXPRESSION REGULATION; GENETIC VECTORS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPASE; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; PPAR ALPHA; PYRIMIDINES; RECEPTORS, LIPOPROTEIN; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANS-ACTIVATORS; TRANSDUCTION, GENETIC; TRIGLYCERIDES; UP-REGULATION;

EID: 36348939261     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.155739     Document Type: Article

References (36)

1. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 2004;24:644-649.
2. Adiels M, Taskinen M-R, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, Yki-Järvinen H, Borén J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765.
3. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1993;13:1110-1118.
4. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850.
5. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, investigators Fs. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
6. Staels B, Fruchart J-C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-2470.
7. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580.
8. Lindén D, Lindberg K, Oscarsson J, Claesson C, Asp L, Li L, Gustafsson M, Borén J, Olofsson SO. Influence of peroxisome proliferator-activated receptor α agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem. 2002;277:23044-23053.
9. Edvardsson U, Ljungberg A, Lindén D, William-Olsson L, Peilot-Sjögren H, Ahnmark A, Oscarsson J. PPARα activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res. 2006;47:329-340.
10. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829-839.
11. Larrouy D, Vidal H, Andreelli F, Laville M, Langin D. Cloning and mRNA tissue distribution of human PPARgamma coactivator-1. Intern J Obes Relat Metab Disord. 1999;23:1327-1332.
12. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem. 2002;277:1645-1648.
13. Meirhaeghe A, Crowley V, Lenaghan C, Lelliott C, Green K, Stewart A, Hart K, Schinner S, Sethi JK, Yeo G, Brand MD, Cortright RN, O'Rahilly S, Montague C, Vidal-Puig AJ. Characterization of the human, mouse and rat PGC1β (peroxisome-proliferator-activated receptor-γ co-activator 1β) gene in vitro and in vivo. Biochem J. 2003;373:155-165.
14. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98:115-124.
15. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, Newgard CB, Spiegelman BM. Bioenergetic analysis of peroxisome proliferator-activated receptor γ coactivators 1α and 1β (PGC-1α and PGC-1β) in muscle cells. J Biol Chem. 2003;278:26597-26603.
16. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, Newgard CB, Spiegelman BM. PGC-1β in the regulation of hepatic glucose and energy metabolism. J Biol Chem. 2003;278:30843-30848.
17. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jäger S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell. 2004;119:121-135.
18. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413:131-138.
19. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nature Med. 2004;10:530-534.
20. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BM. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell. 2005;120:261-273.
21. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20:1868-1876.
22. Lindén D, William-Olsson L, Ahnmark A, Erkoos K, Hallberg C, Sjögren HP, Becker B, Svensson L, Clapham JC, Oscarsson J, Schreyer S. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J. 2006;20:434-443.
23. Véniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arterioscler Thromb Vasc Biol. 2001;21:1567-1570.
24. Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta. 2005;1736:163-180.
25. Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O. Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J Biol Chem. 2005;280:21506-21514.
26. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci of the USA. 1994;91:8724-8728.
27. Dichek HL, Brecht W, Fan J, Ji ZS, McCormick SP, Akeefe H, Conzo L, Sanan DA, Weisgraber KH, Young SG, Taylor JM, Mahley RW. Over-expression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J Biol Chem. 1998;273:1896-1903.
28. Homanics GE, de Silva HV, Osada J, Zhang SH, Wong H, Borensztajn J, Maeda N. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem. 1995;270:2974-2980.
29. Santamarina-Fojo S, González-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1750-1754.
30. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest. 1997;99:846-854.
31. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1β promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 2006;3:99-110.
32. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 2004;432:1027-1032.
33. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly YM, Storlien L, Strömstedt M, Snaith M, Oresic M, Abel ED, Cannon B, Vidal-Puig A. Ablation of PGC-1β results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. Plos Biol. 2006;4:2042-2056.
34. Vianna CR, Huntgeburth M, Coppari R, Choi CS, Lin J, Krauss S, Barbatelli G, Tzameli I, Kim YB, Cinti S, Shulman GI, Spiegelman BM, Lowell BB. Hypomorphic mutation of PGC-1β causes mitochondrial dysfunction and liver insulin resistance. Cell Metab. 2006;4:453-464.
35. Sonoda J, Hehl IR, Chong L-W, Nofsinger RR, Evans RM. PGC-1β controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci U S A. 2007;104:5223-5228.
36. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005;1:361-370.